Corona Remedies IPO Sees Exceptional Demand, Subscribed 144.50x on Day 3

Corona Remedies Limited's initial public offering (IPO) has demonstrated exceptional investor interest through its third day of subscription. The stock price band is set at ₹1008-1062 per share. The ₹655.37 crore IPO reached 144.50 times by 4:59:37 PM on day three. 

Corona Remedies IPO qualified institutional buyers segment leads with exceptional 293.80 times subscription. Non-institutional investors demonstrate exceptional participation at 220.16 times. Retail investors display exceptional interest at 30.33 times. 

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Corona Remedies IPO subscription reached exceptional 144.50 times on day three. It was led by Qualified Institutional Buyers Ex-Anchor (293.80x), Non-Institutional Investors (220.16x), Retail Investors (30.33x), and Employees (15.53x). Total applications reached 41,81,228.

Subscription Status of Corona Remedies IPO:

Here are the subscription details for Corona Remedies IPO as of Day 3 (December 10, 2025, 4:59:37 PM)

Key Highlights - Day 3:

• Overall subscription reached exceptional 144.50 times, showing extraordinary improvement from day two's 9.96 times.
• Qualified institutional buyers (ex-anchor) displaying exceptional interest at 293.80 times, indicating very strong institutional appetite.
• Retail investors displaying exceptional confidence at 30.33 times, indicating robust retail demand.
• Total applications reached 41,81,228, showing exceptional investor participation for this mainboard IPO.
• Cumulative bid amount reached ₹66,545.86 crores, exceeding the net offer size of ₹460.51 crores (excluding anchor portion) by over 144 times.

Corona Remedies IPO - Day 2 Subscription at 9.96 Times

Key Highlights - Day 2:

• Overall subscription reached strong 9.96 times, showing substantial improvement from day one's 0.67 times.
• Non-institutional investors displaying exceptional interest at 28.37 times.
• Retail investors showing strong confidence at 6.90 times.
• Employee category showing strong performance at 4.37 times.
• Qualified institutional buyers showing moderate performance at 1.76 times.

Corona Remedies IPO - Day 1 Subscription at 0.67 Times

Key Highlights - Day 1:

• Overall subscription reached weak 0.67 times, showing cautious initial investor interest.
• Employee category displaying moderate confidence at 1.48 times.
• Retail investors showing limited participation at 0.96 times.
• Non-institutional investors displaying limited interest at 0.84 times.
• Qualified institutional buyers showing negligible participation at 0.00 times.

About Corona Remedies Limited

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas. As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals. The company has a pan-India marketing network and two manufacturing facilities located in Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum. Competitive strengths include being the second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025.